#South Korea #Seoul #CGBIO #KIMES 2026 #FACETEM

CGBIO Showcases Innovation at KIMES 2026

CGBIO, a leading name in regenerative medicine, made waves at the 41st Korea International Medical & Hospital Equipment Show (KIMES 2026), held recently at COEX in Seoul. With a strong focus on aesthetics, wound care, bone and spine solutions, and surgical products, the company not only showcased its innovative medical device portfolio but also signed significant supply agreements worth a staggering KRW 5.3 billion with partners from diverse regions including Singapore, Malaysia, Pakistan, Taiwan, and the Philippines.

At KIMES 2026, CGBIO highlighted several key products that exemplify its commitment to enhancing healthcare technology. Among them is FACETEM, a cutting-edge collagen stimulator that goes beyond traditional fillers by promoting natural collagen production. This innovative approach resonates with the evolving needs of the global aesthetic market, emphasizing both volume enhancement and skin regeneration.

Another star of the show was Curasys ME, a next-generation negative pressure wound therapy device designed with a dual focus on medical efficiency and patient comfort, streamlining the wound care process. Similarly, NOVOSIS has established itself as a leader with its superior osteoinductive properties, further underpinning CGBIO’s expertise in the bone and spine care sector. The company's advanced CG GEL, designed for endoscopic surgeries, demonstrated its effectiveness in managing bleeding during various procedures, showcasing its vital role in surgical settings.

In addition to these flagship products, CGBIO presented a comprehensive suite of medical solutions, including AILEENE, GISELLELIGNE, LUXX, and various others that cater to today's dynamic healthcare landscape. The company is keenly aware of the distinct needs of different markets and has taken strides to tailor its strategies accordingly. Through targeted consultations during the exhibition, CGBIO engaged with international buyers, elucidating the clinical benefits and potential of its diverse product offerings.

The event also served as a pivotal meeting point for establishing new partnerships. CGBIO entered into exclusive supply agreements with Neuva Era for distributing FACETEM in Singapore and Malaysia, as well as with MediNova Healthcare for exclusive distribution rights in Pakistan. Furthermore, agreements were also made with HCT Regenerative Co., Ltd. for distribution of CGDerm One-Step in Taiwan and Variance Trading Corporation for wound care solutions in the Philippines.

According to CGBIO’s CEO, Hyunseung Yu, “KIMES 2026 was an exceptional platform for us to illustrate our strengths as a holistic provider of medical device solutions. Moving beyond a singular product focus, our roundtable discussions and engagements allowed us to showcase how our offerings can create value tailored to the healthcare environments of different countries.” He emphasized the company's commitment to establishing a robust global footprint by aligning product offerings with the specific requirements of each market and building enduring partnerships.

With KIMES 2026 now behind it, CGBIO is poised for continued growth. The company plans to leverage the insights gained from this prominent exhibition to fortify its international strategy, ensuring that it remains at the forefront of the rapidly evolving biomedical sector. CGBIO's participation and achievements at KIMES 2026 not only reinforce its reputation as a leader in regenerative medicine but also signal a commitment to transforming healthcare through innovation.